Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

NCT05233332 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

CRC

Interventions

DRUG: HL-085
DRUG: Vemurafenib

Sponsor

Shanghai Kechow Pharma, Inc.